Virometix Closes Financing Round
Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing
shareholders and new private investors with longstanding experience in the life science sector.
Virometix plans to use the new funds to expand its operations and progress its vaccine candidates for infectious and viral diseases and cancer to next inflections points, including the start of a phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent
safety and strong efficiency in preclinical models. The financing round was substantially oversubscribed.